SCHEMBL2050344

SCHEMBL2050344

CCOC(=O)C(Cc1ccc(CC)cc1)C(C)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.53
TSHR P16473 3/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 4/20 0.44
TP53 P04637 1/20 0.44
NPY1R P25929 1/20 0.43
NPY2R P49146 1/20 0.43
LDHA P00338 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
PKM P14618 1/20 0.41
ACACB O00763 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5326604 0.90 MMP8 (0.53) MMP8TSHRTDP1ALDH1A1TP53
SCHEMBL7696784 0.88 ESR1 (0.51) MMP8ALDH1A1TP53NPY1RNPY2R
SCHEMBL3764833 0.87 MMP8 (0.50) MMP8TSHRTDP1ALDH1A1TP53
SCHEMBL2429506 0.87 PPARG (0.50) MMP8MAPK1TDP1ALDH1A1TP53
SCHEMBL901733 0.87 EPHX2 (0.50) MMP8TSHRALDH1A1TP53NPY1R
SCHEMBL2426124 0.87 MMP8 (0.54) MMP8MAPK1ALDH1A1TP53NPY1R
SCHEMBL856250 0.86 MMP8 (0.69) MMP8TSHRMAPK1L3MBTL1TDP1
SCHEMBL4849611 0.86 PTPRB (0.51) MMP8L3MBTL1TDP1ALDH1A1LDHA
SCHEMBL9231249 0.86 MMP8 (0.50) MMP8TSHRMAPK1TDP1ALDH1A1
SCHEMBL854302 0.85 LDHA (0.63) MMP8TSHRMAPK1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956041-B2 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide AJINOMOTO CO., INC. (JP) 2011-06-07 US disclosed
EP-2163555-A1 New pyrazole derivatives and diabetic medicine containing them Ajinomoto Co., Inc. (JP) 2010-03-17 EP disclosed
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO., INC. (JP) 2010-03-11 US disclosed
US-7645787-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2010-01-12 US disclosed
US-20070270479-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO. INC (JP) 2007-11-22 US disclosed
US-7256209-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2007-08-14 US disclosed
US-7247616-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2007-07-24 US disclosed
US-20070099979-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO. INC (JP) 2007-05-03 US disclosed
US-7015201-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2006-03-21 US disclosed
US-20060058244-A1 New pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2006-03-16 US disclosed
US-20050143424-A1 Prophylactic and therapeutic agent of diabetes mellitus AJINOMOTO CO. INC (JP) 2005-06-30 US disclosed
US-20050043249-A1 New pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2005-02-24 US disclosed
EP-1500403-A1 PREVENTIVE/REMEDY FOR DIABETES Ajinomoto Co., Inc. (JP) 2005-01-26 EP disclosed
US-6815428-B2 AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-09 US disclosed
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2004-01-08 US disclosed
EP-1338603-A1 NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2003-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them SLC5A2, SLC5A1, DPP4 MMP8 1175/4885TSHR 2734/4885MAPK1 1651/4885
US-20070270479-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 MMP8 2536/4885TSHR 2791/4885MAPK1 1638/4885
US-20070099979-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 MMP8 2536/4885TSHR 2791/4885MAPK1 1638/4885
US-20060058244-A1 New pyrazole derivatives and diabetic medicine containing them DPP4, SLC5A2, SLC5A1 MMP8 2536/4885TSHR 2791/4885MAPK1 1638/4885
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 MMP8 2536/4885TSHR 2791/4885MAPK1 1638/4885
US-20050043249-A1 New pyrazole derivatives and diabetic medicine containing them DPP4, SLC5A2, SLC5A1 MMP8 2536/4885TSHR 2791/4885MAPK1 1638/4885
US-20050143424-A1 Prophylactic and therapeutic agent of diabetes mellitus SLC5A2, SLC5A1, GPR119 MMP8 1675/4885TSHR 3004/4885MAPK1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.